The magnitude of the reduction in prostate cancer deaths from population-based PSA screening is too small for a clinical and public health benefit. PSA screening of the general male population ...

Extended follow-up data from the ProtecT trial highlight the importance of weighing the risks associated with radical treatment versus active surveillance for newly diagnosed localized prostate cancer ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

The understanding of prostate cancer has significantly evolved in the past 15 years. Therefore, many people — including primary care providers — may not be aware of the current guidelines for prostate ...

A meta-analysis seeks to determine if adding hormone therapy to radiotherapy after prostatectomy improves overall survival.

Prostate-cancer screening based on prostate-specific antigen (PSA) levels in the blood was introduced—and readily adopted—in the United States around the late 1980s. But this screening method, in ...

About 60% of low‑risk prostate cancer patients are opting for active surveillance — and long‑term survival remains high.

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...

Celebrities have sent prostate cancer’s public profile soaring in recent years. But with accusations that some men are being ...